Oxytocic Pharmaceuticals Market is expected to reach US$ 207.80 Million by 2031

 More than 90% of the global market revenues for oxytocic pharmaceuticals will be harvested from the sales of oxytocic pharmaceuticals originating from synthetic sources. By the end of 2031, an estimated US$ 207.80 million revenues will be emanated from the global sales of synthetic oxytocic pharmaceuticals.

Global Oxytocic Pharmaceuticals Market: Regional Analysis

The need for oxytocic pharmaceuticals in the world will always remain contingent to the rise in pregnancy incidences and birth rate. Various parts of the world exhibit diverse birth rate, which incidentally drives the growth of their oxytocic pharmaceuticals market, accordingly. In North America, oxytocic pharmaceuticals are majorly used for postpartum haemorrhage, which is one of the most-prominent indication among labouring women in the US and Canada.

However, China is expected to remain the largest market for oxytocic pharmaceuticals in the world. Considering the country’s exploding birth rate, China’s oxytocic pharmaceuticals market will be valued over US$ 55 million by 2031-end, expanding at 9.8% CAGR. In 2016, Japan’s oxytocic pharmaceuticals revenues amounted to an estimated US$ 1.7 million, while the oxytocic pharmaceuticals market in Asia-Pacific excluding Japan & China (APEJC) region has been estimated to account for nearly 20% of global revenues.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1445

Global Oxytocic Pharmaceuticals Market: Research Highlights

• Licensing agreements for development of newer oxytocic pharmaceuticals is rampantly boosting the global market revenues, profiting local players as well as industry leaders.
• Surging prevalence of labour induction procedures for child births will continue promoting the use of oxytocic pharmaceuticals throughout the forecast period.
• The global oxytocic pharmaceuticals revenues, however, are projected to witness an inhibited growth on the account of rising preference to alternative drugs such as magnesium sulphate and misoprostol.
• India’s contribution to the APEJC oxytocic pharmaceuticals market is predicted to reach nearly 60% by the end of 2031.
• More than 22,000 thousand units of oxytocic pharmaceuticals will be sold globally for treating labour arrest over the forecast period.
• Hospitals will remain the largest end-user of oxytocic pharmaceuticals in the world, revenues from which will expand beyond 12% CAGR.
• A majority of medical professionals in the world will recommend intravenous administration of oxytocic pharmaceuticals, accounting for more than two-third of global market revenues by the end of 2031.

The Report Segments the Market into Five Sections:

By Indication

• Abortion Induced Incomplete
• Inevitable Abortion
• Post-partum Haemorrhage
• Labour Induction
• Labour Arrest

By Route of administration

• Intravenous Infusion/Injection
• Intramuscular Injection

By Source of Origin

• Natural Oxytocin
• Synthetic Oxytocin Derivative

By End-User

• Hospitals
• Maternity clinics

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan and China (APEJC)
• Japan
• China
• Middle East & Africa (MEA)